About Xofluza® (baloxavir marboxil)
Forward-looking statements
References
1 Press release on November 25, 2019 (PDF)
Shionogi Announces XOFLUZA® Tablets 20mg for the Treatment of Influenza A or B virus Acute Infection Launched in Taiwan.
2 Press release on January 15, 2021
Shionogi Announces Approval of XOFLUZA® (Baloxavir Marboxil) in Taiwan for the Post-Exposure Prophylaxis of Influenza Virus Infection.
3 Hayden FG, et al. N Engl J Med. 2018;379:913–923.
4 Noshi T, et al. Antiviral Res. 2018;160:109–117.
5 Taniguchi K, et al. Sci Rep. 2019;9:3466.
6 Press release on March 14, 2018
XOFLUZATM (Baloxavir Marboxil) Tablets 10mg/20mg for the Treatment of Influenza Types A and B launched in Japan.
7 Press release on November 27, 2020
Shionogi Announces Supplemental New Drug Application for XOFLUZA® in Japan for the Post-Exposure Prophylaxis of Influenza Virus Infection was Approved.
8 Press release on July 4, 2023
Shionogi Filed for a Supplemental New Drug Application of XOFLUZA® (Baloxavir Marboxil) in Taiwan for Pediatrics Aged 5 to Under 12 for the Treatment and Prevention of Influenza Infection.